AIBILI - Association for Innovation and Biomedical Research on Light and Image is a Research Technology Organisation in the health area dedicated to the development and clinical research of new products for medical therapy and diagnostic imaging.
It is a private non-profit organisation, founded in 1989, established to support translational research and technology transfer in the health area. AIBILI is celebrating in 2014 its 25th anniversary.
AIBILI is certified by ISO 9001 since 2004. It is certified for the following activities: performance of clinical studies; planning, coordination, monitoring of clinical research activities; health technology assessment; grading of eye exams; research and development in new technologies for medicine in the areas of imaging, optics and photobiology; and preclinical studies of new molecules with potential medical use.
Clinical trials are performed in accordance with ICH Guidelines for Good Clinical Practice (GCP).
Pharmacovigilance: Updates on drug safety is a quarterly publication issued by the Portuguese Central Regional Pharmacovigilance Unit (UFC) delivering to patients and healthcare professionals information on the risks and safe use of medicines. Farmacovigilância: Atualizações de segurança de medicamentos é uma publicação trimestral editada pela Unidade de Farmacovigilância do Centro (UFC) com o objetivo de disponibilizar informação de segurança dos medicamentos aos utentes e profissionais de saúde.
Micro-Aneurysm Formation Rate as calculated by a validated automated method seems a very promising biomarker for enriching a patient population at higher risk for the development of Clinically Significant Macular Oedema. The Retmarker Company (formerly known as Critical Health) is in a process to qualify the Micro-Aneurysm Formation Rate (MAFR), measured with a validated automated method as an enrichment biomarker for studies of clinically significant macular oedema (CSMO), a sight-threatening complication of Diabetic Retinopathy (DR). Such biomarker could be used to enrich a clinical trial population to those at higher risk of developing CSMO. Please download here the press release.
Please find here the available opportunity.
If you wish any further information e-mail us at firstname.lastname@example.org.